People default image

Josh Seidenfeld

Partner
Chair, Northern California Corporate and Securities practice
Palo Alto (Silicon Valley)
About

Josh Seidenfeld represents technology, life sciences and healthcare companies throughout the corporate lifecycle – from seed stage through private financings, mergers and acquisitions (M&A), and initial public offerings (IPOs). He regularly advises on general corporate matters, securities compliance, and the structuring and implications of strategic transactions.

In the past year, Josh has led transactions totaling billions of dollars on a variety of matters ranging from venture financings to mergers and public offerings.

He counsels businesses across the biotechnology, therapeutics, pharmaceutical, climate technology and energy, digital health, medical technology, and software sectors, including emergent AI.

Areas of FocusCorporateEmerging Growth and Venture CapitalTechnologyLife SciencesHealthcare
Bar admissionsCalifornia
Education
  • JD, Santa Clara University School of Law
  • MBA, Santa Clara University Leavey School of Business
  • BS, University of California, Riverside

EXPERIENCE

  • An AI healthcare technology platform’s USD111 million Series A financing
  • A cell therapy integrated development and manufacturing organization’s USD255 million Series C financing
  • A late-stage biotechnology company’s USD192 million Series B financing
  • A genomic data company’s USD200 million Series B financing
  • A clinical-stage biotherapeutics company’s USD73 million IPO
  • A technology-focused venture capital firm’s investment in a mobile gaming publisher’s USD20 million Series A financing
  • A biotechnology company’s USD125 million Series C financing
  • A unified endpoint management and mobile device management platform’s USD100 million IPO
  • A biotechnology company’s USD110 million IPO
  • A cloud-based software platform’s acquisition of a cloud-based management and booking system for USD150 million
  • An epigenomics research and development company’s sale to a genomic biotechnology company
  • An open-source business intelligence platform’s acquisition by an enterprise software company for USD185 million
  • A medical technology company’s acquisition of the obesity intervention division of a pharmaceutical company for USD110 million
  • A clinical-stage biotechnology company’s merger with a biopharmaceutical company for USD150 million
  • A digital entertainment company’s acquisition of a software company
  • A global video streaming service’s acquisition by a Japanese technology conglomerate
  • A customer loyalty marketing company’s acquisition by a customer experience management company
  • A technology-focused investment fund’s lead USD1.1 billion equity investment in a biopharmaceutical company
  • A cloud-based analytics company’s USD46 million Series C financing
  • A privately held medical device company’s equity and debt financing
  • A wireless networking brand’s acquisition by an online retailer and provider of cloud services

Prior Experience

Josh previously served as global chair of a global law firm’s digital health group and served on the firm’s Life Sciences Advisory Board. He also worked in the healthcare industry at Practice Fusion , a web-based electronic health records company, where he was corporate counsel and director of business development.

Connect

Phone

+1 650 833 2121
(Work, Palo Alto)
CallvCardLinkedInPrint